https://audiomedica.com/episode/peter-schmid-md-phd-asco-2026-giredestrant-beats-standard-endocrine-therapies-irrespective-of-menopausal-status-in-patients-with-er-her2-early-breast-cancer
Peter Schmid MD PhD; ASCO 2026: Giredestrant Beats Standard Endocrine Therapies Irrespective of...
Jun 5, 2026 - Giredestrant Beats Standard Endocrine Therapies Irrespective of Menopausal Status in Patients with ER+, HER2- Early Breast Cancer An interview with: Peter…
peter schmidmd phdirrespective ofascogiredestrant
https://www.pharmanow.live/es/latest-news/roche-giredestrant-phase3-pfs-benefit-er-positive-breast-cancer
Datos de PFS de la Fase 3 de Roche Giredestrant: impacto en la fabricación | Pharma Now
El giredestrant de Roche alcanza el criterio de valoración de SSP en fase 3 en cáncer de mama ER+/HER2-. Implicaciones clave para el abastecimiento de API, la...
datospfsfaserochegiredestrant
https://www.curecancerwithai.com/news/breakthrough-in-advanced-breast-cancer-treatment-giredestrant-shows-promise
Breakthrough in Advanced Breast Cancer Treatment: Giredestrant Shows Promise | Cure Cancer With AI...
Oct 3, 2026 - Recent findings from the phase 3 evERA study reveal a significant advancement in the treatment of estrogen-receptor-positive (ER+) HER-2-negative advanced br...
advanced breast cancerbreakthroughtreatmentgiredestrantshows